Orgenesis (ORGS) Competitors $2.15 +0.49 (+29.53%) As of 02/21/2025 03:44 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends ORGS vs. AKTX, NKGN, PULM, CMMB, LEXX, CYTH, GDTC, ALLK, CDIO, and JATTShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Akari Therapeutics (AKTX), NKGen Biotech (NKGN), Pulmatrix (PULM), Chemomab Therapeutics (CMMB), Lexaria Bioscience (LEXX), Cyclo Therapeutics (CYTH), CytoMed Therapeutics (GDTC), Allakos (ALLK), Cardio Diagnostics (CDIO), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Akari Therapeutics NKGen Biotech Pulmatrix Chemomab Therapeutics Lexaria Bioscience Cyclo Therapeutics CytoMed Therapeutics Allakos Cardio Diagnostics JATT Acquisition Orgenesis (NASDAQ:ORGS) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk & volatility, ORGS or AKTX? Orgenesis has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ORGS or AKTX? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 38.9% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ORGS or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Akari Therapeutics N/A N/A N/A Does the media favor ORGS or AKTX? In the previous week, Akari Therapeutics had 4 more articles in the media than Orgenesis. MarketBeat recorded 4 mentions for Akari Therapeutics and 0 mentions for Orgenesis. Akari Therapeutics' average media sentiment score of 0.13 beat Orgenesis' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Orgenesis Neutral Akari Therapeutics Neutral Which has preferable valuation & earnings, ORGS or AKTX? Akari Therapeutics has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$530K19.47-$55.36MN/AN/AAkari TherapeuticsN/AN/A-$10.01MN/AN/A Does the MarketBeat Community believe in ORGS or AKTX? Akari Therapeutics received 261 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 50.68% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesAkari TherapeuticsOutperform Votes26250.68% Underperform Votes25549.32% SummaryAkari Therapeutics beats Orgenesis on 7 of the 11 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.97M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.8226.1519.13Price / Sales19.47268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book-0.336.717.644.62Net Income-$55.36M$138.55M$3.19B$245.94M7 Day Performance39.61%-2.63%-2.11%-2.62%1 Month Performance43.33%-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$2.15+29.5%N/AN/A$7.97M$530,000.000.00150High Trading VolumeAKTXAkari TherapeuticsN/A$1.08-0.3%N/A-58.6%$28.69MN/A0.009Analyst ForecastNews CoverageGap DownNKGNNKGen BiotechN/A$0.63-17.9%N/A-40.1%$28.36M$80,000.00-0.12N/ANews CoverageGap UpHigh Trading VolumePULMPulmatrix0.0789 of 5 stars$7.73+3.2%N/A+404.0%$28.21M$7.30M-2.9320CMMBChemomab Therapeutics2.9666 of 5 stars$1.96-1.0%$7.50+282.7%+153.0%$28.14MN/A-1.9620Analyst ForecastNews CoverageLEXXLexaria Bioscience3.4102 of 5 stars$1.60+4.6%$9.50+493.8%-35.6%$28.08M$460,000.00-3.207CYTHCyclo Therapeutics0.9525 of 5 stars$0.98-6.2%$0.95-2.6%-45.8%$28.07M$1.08M-1.089News CoverageGap DownHigh Trading VolumeGDTCCytoMed Therapeutics2.2476 of 5 stars$2.56+2.4%$5.00+95.3%+18.1%$28.01MN/A0.00N/AALLKAllakos4.225 of 5 stars$0.31+5.1%$2.00+539.6%-77.8%$27.94MN/A-0.15190CDIOCardio Diagnostics1.8 of 5 stars$0.67-1.2%$2.00+198.8%-68.1%$27.07M$20,000.000.001Gap UpJATTJATT AcquisitionN/A$1.55+3.3%N/A-61.9%$26.74MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Akari Therapeutics Alternatives NKGen Biotech Alternatives Pulmatrix Alternatives Chemomab Therapeutics Alternatives Lexaria Bioscience Alternatives Cyclo Therapeutics Alternatives CytoMed Therapeutics Alternatives Allakos Alternatives Cardio Diagnostics Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
